https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3AGLP-1_receptor_agonist%2F5%2FenTranslations:GLP-1 receptor agonist/5/en - Revision history2026-10-02T16:07:51ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:GLP-1_receptor_agonist/5/en&diff=110955&oldid=prevFuzzyBot: Importing a new version from external source2024-02-05T12:59:56Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>==Indications==<br />
===Type 2 diabetes===<br />
GLP-1 agonists were developed initially for [[type 2 diabetes]]. The 2022 [[American Diabetes Association]] (ADA) standards of medical care in diabetes include GLP-1 agonist or [[SGLT2 inhibitor]] as a first line [[pharmacological therapy]] for type 2 diabetes in patients who have or are at high risk for [[atherosclerotic cardiovascular disease]] or [[heart failure]]. They are also a first line treatment for people with both type 2 diabetes and kidney disease. Both types of medication can be combined with [[metformin]]. One of the advantages of GLP-1 agonists over older [[anti-diabetic medication#Secretagogues|insulin secretagogues]], such as [[sulfonylurea]]s or [[meglitinide]]s, is that they have a lower risk of causing [[hypoglycemia]]. The ADA also recommends use of GLP-1 agonists instead of starting insulin in people with type 2 diabetes who need additional glucose control, except where there is catabolism, hyperglycemia above a certain threshold, or autoimmune diabetes is suspected.</div>FuzzyBot